(^14) COMPANY NEWS l BIOSPECTRUM | SEPTEMBER 2018 | http://www.biospectrumindia.com
Sanofi Pasteur, the vaccine
division of Sanofi, recently
announced the launch of its
4-strain influenza vaccine
FluQuadri in India. FluQuadri
will be India’s first quadrivalent
vaccine to provide broader
protection against influenza
to population above 3 years of
age. Currently, the majority
of seasonal influenza vaccines
are trivalent, meaning that they
protect against: two A strains and
one single B lineage (B/Victoria
or B/Yamagata) of Influenza
virus. However, over the recent
flu seasons, co-circulation of both
B lineages has been consistently
observed, making it difficult for
the World Health Organization
(WHO) to recommend which B
strain should be incorporated
in trivalent influenza
vaccines. Given the change in
epidemiology, quadrivalent
vaccination represent the next
logical step to an advanced level
of protection. The WHO includes
quadrivalent influenza vaccines
in its recommendations, stating
that Quadrivalent influenza
vaccines that could potentially
provide wider protection against
influenza B viruses are becoming
available and recommendations
should not be limited to trivalent
vaccine.
Singapore health-tech firm
Symple Wellness Platform,
which operates under the
Vivant brand, has acquired
Pune-based wellness and
health analytics platform
AllizHealth. AllizHealth is a
consumer-focused wellness
and health analytics platform
for early identification,
tracking and management of
health risks and conditions.
Vivant offers services including
digital health records, health
risk assessments, doctor
consults, health check-ups,
health coaches and condition
management programs.
AllizHealth was founded
by Chinmoy Mishra, Rasmi
Mishra, Gaurav Vij and Dhairya
Gupta in 2013. It has a team
of 40 people across various
functions. All co-founders
except Gupta will remain with
Vivant after the acquisition.
Chinmoy Mishra will be chief
business development officer,
Rasmi Mishra will be chief
product innovation officer and
Vij will be chief technology
officer.
Wockhardt has set up its first facility
in Middle East for manufacturing
of NCEs (New Chemical Entities)
catering to the global markets
through its Dubai arm of its
subsidiary Wockhardt Bio AG.
With an aim to grow and further
establish their international presence
in pharmaceutical manufacturing,
Wockhardt recently inaugurated
a ‘state-of-the-art’ manufacturing
facility for the production and
packaging of sterile dry powder
injection in Dubai. On approval
of the new drug by US FDA, this
manufacturing facility will be
commissioned for commercial
production. Wockhardt Bio AG
manufacturing facility is designed
to meet standards of various
international regulatory agencies
and the standards as set by the Local
Ministry of Health. The facility meets
the needs of Aseptic Dry Powder
Injectable manufacturing and filling
with a high quality operation. This
facility is dedicated to launch its
novel New Chemical Entities in the
Antibiotics segment to the world
from UAE.
Sanofi Pasteur releases FluQuadri vaccine
Wockhardt sets
up manufacturing
facility in Dubai
Singapore firm acquires
Pune based platform
singke
(singke)
#1